Filing Details

Accession Number:
0001209191-20-050590
Form Type:
4
Zero Holdings:
No
Publication Time:
2020-09-15 19:22:28
Reporting Period:
2020-09-11
Accepted Time:
2020-09-15 19:22:28
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1422143 Kura Oncology Inc. KURA Pharmaceutical Preparations (2834) 611547851
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1589597 Edward Troy Wilson C/O Kura Oncology, Inc.
12730 High Bluff Drive, Suite 400
San Diego CA 92130
President And Ceo Yes Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2020-09-11 17,926 $6.15 46,022 No 4 M Direct
Common Stock Disposition 2020-09-11 17,926 $28.00 28,096 No 4 S Direct
Common Stock Disposition 2020-09-11 485 $28.00 305,226 No 4 S Indirect by Araxes Pharma LLC
Common Stock Disposition 2020-09-14 98,490 $28.82 206,736 No 4 S Indirect by Araxes Pharma LLC
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
No 4 S Indirect by Araxes Pharma LLC
No 4 S Indirect by Araxes Pharma LLC
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Option to purchase common stock Disposition 2020-09-11 17,926 $0.00 17,926 $6.15
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
157,021 2027-01-22 No 4 M Direct
Reported Non-Derivative Holdings
Sec. Name Remaning Holdings Nature of Ownership Explanation
Common Stock 1,795,017 Indirect by Red Fish Blue Fish Revocable Trust
Footnotes
  1. The transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 11, 2019 and amended on December 23, 2019 and June 8, 2020.
  2. The transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 23, 2019 and amended on June 8, 2020.
  3. This transaction was executed in multiple trades at prices ranging from $28.00 to $29.95. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
  4. This option vests in 48 equal monthly installments commencing on January 23, 2017.